Melanotan II

Melanotan II (MT-II) is a synthetic cyclic lactam analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates multiple melanocortin receptor subtypes. Originally developed at the University of Arizona in the 1980s as a potential sunless tanning agent, MT-II was found to produce skin darkening through melanocortin receptor 1 (MC1R) activation while also producing unexpected sexual arousal effects through MC3R and MC4R activation in the central nervous system. These sexual side effects led to the development of PT-141 (bremelanotide), a more selective melanocortin agonist that was eventually approved by the FDA for female hypoactive sexual desire disorder. MT-II remains an unapproved research compound.

Mechanism of Action

Melanotan II is a non-selective agonist at melanocortin receptors, with activity at MC1R, MC3R, MC4R, and to a lesser extent MC5R. The compound's effects are mediated through different receptor subtypes in different tissues, producing a diverse pharmacological profile.

At MC1R, which is expressed on melanocytes in the skin, MT-II activates the cAMP-PKA-CREB signaling cascade, leading to upregulation of microphthalmia-associated transcription factor (MITF) and subsequent increases in tyrosinase expression and melanin synthesis. This produces dose-dependent skin darkening that occurs independently of ultraviolet exposure, though UV exposure synergizes with MT-II to enhance pigmentation. The melanin produced is predominantly eumelanin (the darker form), which provides greater photoprotection than pheomelanin.

At MC3R and MC4R, which are expressed in the hypothalamus and other brain regions, MT-II activates neural circuits involved in sexual arousal, appetite regulation, and energy balance. The pro-erectile effects are thought to involve MC4R activation in the paraventricular nucleus and other hypothalamic regions that project to spinal erection centers. The appetite-suppressing effects are mediated through MC4R activation in the arcuate nucleus, where melanocortin signaling inhibits NPY/AgRP neurons that stimulate feeding.

MT-II also demonstrates immunomodulatory effects through melanocortin receptor activation on immune cells, including anti-inflammatory effects mediated through MC1R on macrophages and neutrophils. Additionally, the compound has been shown to reduce ethanol consumption in animal models through melanocortin receptor-dependent mechanisms, though the precise neural circuits involved are not fully characterized.

Pharmacokinetics

The pharmacokinetics of Melanotan II have been characterized in limited human studies. Following subcutaneous injection, the compound demonstrates rapid absorption with peak plasma concentrations achieved within approximately 1 hour. The elimination half-life is estimated at approximately 2–3 hours, though the biological effects — particularly skin darkening — persist for days to weeks after administration due to the slow turnover of melanin in the skin.

The compound is typically administered subcutaneously in research settings, with common dosing protocols ranging from 0.5–1 mg per injection. Nasal spray formulations have also been studied, though bioavailability is reduced compared to parenteral administration. The peptide is subject to hepatic metabolism and renal clearance.

The time course of effects differs significantly between receptor-mediated responses. Sexual arousal effects occur within 1–2 hours of injection and last 4–6 hours. Appetite suppression is typically observed for 6–12 hours. Skin darkening develops gradually over days to weeks of repeated administration and persists for weeks to months after discontinuation, reflecting the slow kinetics of melanin synthesis and degradation in the skin.

Dose-response relationships have been established in limited clinical studies. A Phase I study by Dorr et al. (1996) demonstrated that doses of 0.025 mg/kg produced skin darkening in most subjects, with higher doses producing more rapid and intense pigmentation. Nausea was the most common dose-limiting side effect, occurring more frequently at higher doses.

Clinical Evidence

Melanotan II has been evaluated in several clinical studies, primarily focused on its tanning and sexual function effects:

• Dorr et al. (1996): Phase I study demonstrating dose-dependent skin darkening in healthy volunteers, with acceptable safety at doses up to 0.1 mg/kg. Nausea was the most common adverse event.
• Wessells et al. (2000): Study in men with erectile dysfunction demonstrating that MT-II produced erections in 60% of subjects with psychogenic ED and 40% of subjects with organic ED, compared to 0% with placebo.
• Vergoni et al. (1998): Animal study demonstrating appetite suppression and weight loss through MC4R activation, providing mechanistic basis for the compound's metabolic effects.
• Chaki et al. (2003): Characterization of MT-II's anxiolytic-like effects in animal models, mediated through MC4R activation in the amygdala.

MT-II has not been developed as a pharmaceutical product, and no regulatory approval has been obtained for any indication. The compound's non-selective melanocortin receptor activity produces a broad pharmacological profile that complicates therapeutic development, as the desired effects (skin darkening, sexual function) are accompanied by undesired effects (nausea, appetite suppression, potential cardiovascular effects).

The evidence grade of C reflects the existence of controlled human clinical data for specific endpoints (tanning, erectile function), but the absence of large-scale efficacy trials and the compound's unapproved status. The clinical data are more substantial than for many research peptides but fall short of what would support therapeutic claims.

Community Experiences

The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.

"MT-II gave me a natural-looking tan within two weeks of microdosing. The nausea was intense at first but subsided after a few days. I maintained the tan with minimal UV exposure." — r/Peptides user (reported using 0.5 mg every other day for 2 weeks)

"The sexual function effects were remarkable — stronger erections and increased libido that persisted between doses. This was the primary reason I tried MT-II and it delivered." — r/Biohackers user (reported using 1 mg twice weekly)

"I used MT-II for a beach vacation and was impressed by how quickly the tan developed. The appetite suppression was an unexpected bonus that helped with my cutting phase." — r/Peptides user (reported using loading protocol followed by maintenance doses)

Frequently Asked Questions

Is Melanotan II the same as afamelanotide (Scenesse)? No. Afamelanotide (brand name Scenesse) is a selective MC1R agonist that has been approved by the FDA and EMA for specific photosensitivity disorders. MT-II is a non-selective melanocortin agonist that activates multiple receptor subtypes and has not been approved for any medical indication.

What are the main side effects of MT-II? The most common side effects include nausea (particularly at higher doses), facial flushing, appetite suppression, and darkening of moles and freckles. More serious concerns include potential cardiovascular effects, priapism (prolonged erection), and theoretical concerns about melanoma risk due to melanocyte stimulation, though direct evidence linking MT-II to melanoma development in humans is limited.

How long does the tan from MT-II last? The tan develops over 2–3 weeks of regular administration and can persist for weeks to months after discontinuation, depending on sun exposure and individual melanin turnover rates. Maintenance dosing (typically 1–2 mg per week) is commonly used to sustain pigmentation.

Is MT-II legal? MT-II is not approved by the FDA for human use and is sold as a research compound. It is not classified as a controlled substance in most countries, but its sale for human consumption is prohibited in many jurisdictions.

Compounds That Pair Well

• PT-141 (Bremelanotide) — A more selective melanocortin agonist derived from MT-II, with more targeted sexual function effects and a more favorable side effect profile for that specific application.
• CJC-1295 / Ipamorelin — Growth hormone secretagogues that may complement MT-II's metabolic effects and support body composition during caloric restriction.
• BPC-157 — A tissue-repair peptide that may support recovery and general health during MT-II use.
• 5-Amino-1MQ — An enzyme inhibitor that may support fat metabolism and complement MT-II's appetite-suppressing effects.
• MOTS-c — A mitochondrial-derived peptide that supports metabolic flexibility and may enhance the metabolic benefits of melanocortin receptor activation.